Pfiz­er, Mer­ck KGaA tout PhI­II suc­cess for Baven­cio; Im­mun­sanT gets a new in­vest­ment from JDRF

→ Pfiz­er and Mer­ck KGaA say their Phase III study of the check­point drug Baven­cio com­bined with In­ly­ta came through for re­nal cell car­ci­no­ma pa­tients, set­ting up some speedy ap­pli­ca­tions for mar­ket­ing ap­proval. Re­searchers say it came through with PD-L1 ex­press­ing pa­tients and the full pop­u­la­tion, demon­strat­ing a sig­nif­i­cant PFS ben­e­fit com­pared to a con­trol arm treat­ed with Su­tent. “JAVELIN Re­nal 101 is the first pos­i­tive Phase III study com­bin­ing an im­mune check­point block­er with a TKI, sup­port­ing the po­ten­tial of BAVEN­CIO and IN­LY­TA as a new can­cer treat­ment ap­proach for pa­tients with ad­vanced RCC,” said Chris Boshoff, Pfiz­er’s head of im­muno-on­col­o­gy, ear­ly de­vel­op­ment and trans­la­tion­al on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER